The release of a new FDA-cleared genetic report on Simvastatin by 23andMe could potentially increase the company's market share in the genetic testing industry. This is because the report could attract more consumers who are interested in understanding their genetic response to commonly prescribed medications like Simvastatin. The fact that 23andMe is the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports could also give it a competitive advantage in the industry.